← Every applicant
Actavis Labs Fl Inc FDA Approvals
10 new drug approvals and 0 device clearances on file. This applicant is not matched to a listed company.
Newest first
A new drug approval is an original application; a 510(k) is a device shown equivalent to one already sold.
| Product |
|---|
| RIFAXIMINNew drugMar 19, 2026TABLET, ORAL |
| PHENTERMINE HYDROCHLORIDE AND TOPIRAMATENew drugJun 25, 2024CAPSULE, EXTENDED RELEASE, ORAL |
| AMPHETAMINENew drugJun 22, 2023TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE, ORAL |
| GEFITINIBNew drugApr 26, 2023TABLET, ORAL |
| LACOSAMIDENew drugJan 5, 2023TABLET, ORAL |
| FESOTERODINE FUMARATENew drugJan 4, 2023TABLET, EXTENDED RELEASE, ORAL |
| POSACONAZOLENew drugNov 30, 2022TABLET, DELAYED RELEASE, ORAL |
| NAPROXEN AND ESOMEPRAZOLE MAGNESIUMNew drugAug 24, 2022TABLET, DELAYED RELEASE, ORAL |
| DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDENew drugMar 1, 2022TABLET, EXTENDED RELEASE, ORAL |
| ENZALUTAMIDENew drugMay 14, 2021CAPSULE, ORAL |